REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Start Date
3/9/2026
Completion Date
5/6/2030
Summary
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
REGN7508
Placebo
Conditions
Locations
Bioresearch Partner- Hialeah Hospital
Hialeah, Florida 33013
United States
Helios Clinical Research
North Miami Beach, Florida 33169
United States
El Paso Medical Research Institute (Medresearch Inc)
El Paso, Texas 79902
United States
LTD High Technology Hospital Medcenter
Batumi, Adjara 6000
Georgia
Krystyna Kiel Oncology Center
Kutaisi, Imereti 4600
Georgia
American Hospital Tbilisi
Tbilisi, 0102
Georgia
Llc Todua Clinic
Tbilisi, 0112
Georgia
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
Tbilisi, 0144
Georgia
Institute of Clinical Oncology
Tbilisi, 0159
Georgia
JSC Evex Hospitals - Caraps Medline
Tbilisi, 0179
Georgia
LTD Cancer Research Centre
Tbilisi, 0179
Georgia
Caucasus Medical Centre
Tbilisi, 0186
Georgia
Yamaguchi University Hospital
Ube, Yamaguchi 755-8505
Japan